Author's response to reviews

Title: Identification and validation of dysregulated MAPK7 (ERK5) as a novel oncogenic target in squamous cell lung and esophageal carcinoma

Authors:

Paul R Gavine (paul.gavine@astrazeneca.com)
Mei Wang (Mei.wang@astrazeneca.com)
De-Hua Yu (yudehua@yahoo.com)
Eva Yu (eva.hu@astrazeneca.com)
Chunlei Huang (chunlei.huang@astrazeneca.com)
Jenny Xia (jenny.xia@astrazeneca.com)
Xinying Su (Xinying_su@astrazeneca.com)
Joan Fan (joan.fan@astrazeneca.com)
Tianwei Zhang (Tianwei.zhang@astrazeneca.com)
Qingqing Ye (yeqinqing616@163.com)
Li Zheng (Li.zheng@astrazeneca.com)
Guanshan Zhu (Guanshan_zhu@hotmail.com)
Ziliang Qian (zl_qian@aliyun.com)
Qingquan Luo (luoqingguan@hotmail.com)
Yingyong Huo (houyingyong@medmail.com.cn)
Qunsheng Ji (Qunsheng.ji@astrazeneca.com)

Version: 5 Date: 27 April 2015

Author's response to reviews: see over
Dear Sir/Madam,

Please find below our point-by-point response to the second set of reviewers comments.

Referee 1:

- “The authors have addressed my concerns. I agree that further studies could be conducted in the future to characterize the contribution of kinase activity of MAPK7 in carcinogenesis. I have only one concern. Please note that error bars cannot be included for technical replicates. Please see (Cumming et al JCB 2007, Vaux et al 2012, EMBO rep.).”
- We have now removed the error bars from Figure 4Band have uploaded this revised version titled “Figure4-REVISED v2”.

Yours faithfully,

Paul R.Gavine. PhD.